- BriaCell Therapeutics (TSX:BCT) reveals it has initiated a Phase 1/2 clinical trial to evaluate the safety and efficacy of Bria-OTS™, a personalized immunotherapy, for metastatic breast cancer.
- The study will test Bria-OTS™ both as a monotherapy and in combination with BeiGene’s anti-PD-1 antibody, tislelizumab®
- The trial will focus on patients with metastatic or recurrent breast cancer who have failed at least two prior systemic therapies, such as chemotherapy or immune checkpoint inhibitors.
- Shares of BriaCell Therapeutics are up 21.18 per cent to C$1.03 as of 12:09 p.m. ET
BriaCell Therapeutics (TSX: BCT) reveals the dosing of the first patient in its Phase 1/2 clinical trial, which aims to evaluate the safety and efficacy of Bria-OTS™, which is a personalized immunotherapy developed by the company, will be evaluated in patients with metastatic breast cancer.
In a press release, the company stated that Bria-OTS™ is an enhanced version of Bria-IMT™, BriaCell’s immunotherapy platform currently being evaluated in a pivotal Phase 3 study for metastatic breast cancer.
The trial will target patients with metastatic or recurrent breast cancer who have failed at least two prior systemic therapies, such as chemotherapy or immune checkpoint inhibitors.
“Oncologists have long been seeking new treatments for metastatic cancer patients who progress after antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (CPIs). We have been impressed by the survival and clinical benefit data from Bria-IMT™ and are excited to explore the potential of Bria-OTS™ in this new study,” Dr. Sant P. Chawla, MD, FRACP and head of the Sarcoma Oncology Center and principal investigator of the study, said in a release.
The Phase 1/2 study will proceed in two phases: a dose escalation phase to evaluate Bria-OTS™ as a monotherapy, followed by an expansion phase to assess the combination therapy with tislelizumab®. The study will also lay the groundwork for future trials investigating Bria-OTS™ in other cancer types, including prostate cancer.
“Dosing the first patient with Bria-OTS™ marks a new chapter in cancer immunotherapy. This novel technology represents a major step forward in cellular immunotherapy, offering hope for patients in need of advanced treatment options,” Dr. Giuseppe Del Priore, MD, MPH and chief medical officer at BriaCell, said in a statement.
Bria-OTS™ is designed to provide superior efficacy and synergy with immune checkpoint inhibitors, making it a personalized, off-the-shelf cancer therapy.
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
Shares of BriaCell Therapeutics are up 21.18 per cent to C$1.03 as of 12:09 p.m. ET.
Join the discussion: Find out what everybody’s saying about this stock on the BriaCell Therapeutics Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: Adobe Stock, generated by AI)
